News January 9, 2023 - Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG Read More July 11, 2022 - Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes Read More July 11, 2022 - Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors Read More February 2, 2022 - CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) Read More January 26, 2022 - Preclinical Study Provides Guidance for Optimizing Safety and Efficacy of Endovascular Hepatic Denervation Devices to Treat Diabetes Read More January 5, 2022 - Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes Read More December 17, 2021 - Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG Read More July 26, 2021 - In Memoriam, Robert McNeil (1943 – 2021) Read More June 29, 2021 - Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients Read More June 29, 2021 - Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screen for adrenal insufficiency? Read More